Isis earns milestone payment from Biogen

In a regulatory filing, Isis Pharmaceuticals (ISIS -3.1%) discloses that it earned an $18M milestone payment from development partner Biogen Idec (BIIB -1.1%)  by virtue of dosing the first infant in the ENDEAR Phase 3 clinical trial evaluating ISIS-SMNrx as a treatment for spinal muscular dystrophy.

From other sites
Comments (5)
  • chicagomary
    , contributor
    Comments (384) | Send Message
    one of my favorite things about SA is their ability to get these filings out even before my broker. :)
    21 Aug 2014, 04:47 PM Reply Like
  • Doc's Trading
    , contributor
    Comments (1847) | Send Message
    TSLA....Lower buy stop on short sale taken at 263 from 260.20 to 257.55 stop.


    This is our 63rd recommendation of 64 made since Feb 15 of which 57 have been profitable for 470 points profit, 3 losses for 12 points loss and four still working...all profitable.
    more later....
    21 Aug 2014, 05:04 PM Reply Like
  • chicagomary
    , contributor
    Comments (384) | Send Message
    why is this on a stock talk about $ISIS?
    21 Aug 2014, 05:09 PM Reply Like
  • salvatort
    , contributor
    Comments (411) | Send Message
    Perhaps they should consider changing their ticker now...
    21 Aug 2014, 05:23 PM Reply Like
  • IncomeYield
    , contributor
    Comments (3700) | Send Message
    yup -- gotta change the name
    21 Aug 2014, 11:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs